Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABLE OA: Autologous Cellular Preparations for Knee Osteoarthritis
NCT05517434Phase 3Recruiting
- Sponsor
- University Health Network
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bone marrow aspirate and Leukocyte-Poor Platelet Rich Plasma in osteoarthritis (OA) (4 arms), sponsored by University Health Network. Primary endpoint: Numeric Pain Rating Scale Response Rate at 6 months. Started Jan 2025; status: recruiting.
02
Drugs
bone marrow aspirateLeukocyte-Poor Platelet Rich Plasma
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05517434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517434.